Actively Recruiting
A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
Led by M.D. Anderson Cancer Center · Updated on 2026-02-19
170
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to observe complications and clinical responses in patients with advanced cancers, including hematopoietic, lymphoid cell neoplasms, and malignant solid neoplasms, who are treated with therapies related to anti-VEGF. The study seeks to understand if side effects from these treatments relate to how the disease responds, helping doctors learn more about treatment impact. It is a prospective observational study conducted by M.D. Anderson Cancer Center, analyzing patient outcomes over time. The study involves reviewing medical records of cancer patients receiving anti-VEGF-related therapies, either alone or combined with other treatments. There are no active treatments administered as part of the study; rather, it focuses on collecting and analyzing existing clinical data on treatment complications and effectiveness. Data collection covers various side effects, including those graded 3 or higher, and explores a novel blood pressure scoring system to assess correlations with treatment response. Participants are involved through the review of their medical records, with no direct visits or interventions required. Researchers will track the incidence of serious adverse events possibly related to anti-VEGF treatments for up to five years. The study evaluates clinical outcomes and safety information by reviewing patient records, with results aiming to improve understanding of treatment risks and responses in cancer care.
CONDITIONS
Brief Title
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be able to understand and be willing to sign a written informed consent document
- Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants' medical records are reviewed to evaluate complications and clinical responses related to anti-VEGF therapies.
Records are reviewed periodically throughout the study duration
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here